ACE2 and COVID-19: Therefore, it is not clear how COVID-19 comorbid patients having a high constitutive amount of circulating ACE2 may benefit from rACE2 administration, ultimately suggesting that the assumption that the ACE2 activity is down-regulated by SARS-CoV-2 may not be correct.